

**BME - GROWTH**

Palacio de la Bolsa  
Plaza de la Lealtad, 1  
28014 Madrid

Alicante, 19th of January 2024

**COMMUNICATION- PRIVILEGED INFORMATION- FACEPHI BIOMETRIA, S.A.**

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the Law 6/2023 17<sup>th</sup> March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

Facephi and Nice & Green (the investor) have agreed to sign an amendment to modify certain investment agreement's conditions announced last 5<sup>th</sup> of May 2023.

Modifications are the following:

- It is agreed to reduce the maximum amount that the investor can invest from the initially agreed EUR 20 million to EUR 11.1 million.
- The amount currently pending to be invested is 4.2 million euros (420 bonds). With regard to this amount, it is agreed that Facephi can issue up to 7 tranches of 60 convertible bonds (600,000 €) at one-month intervals.

All other circumstances and agreements between the parties remain unchanged.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

---

Javier Mira Miró

**Chairman of the Board of Directors**